Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. DiMasi, R. Hansen, H. Grabowski (2003)
The price of innovation: new estimates of drug development costs.Journal of health economics, 22 2
D. Altman (1998)
Confidence intervals for the number needed to treatBMJ, 317
A. Laupacis, D. Sackett, R. Roberts (1988)
An assessment of clinically useful measures of the consequences of treatment.The New England journal of medicine, 318 26
S. Walter (2001)
Number needed to treat (NNT): estimation of a measure of clinical benefitStatistics in Medicine, 20
R. Carroll, D. Ruppert, L. Stefanski (1995)
Measurement Error in Nonlinear Models
A. Tonkin, P. Alyward, D. Colquhoun, P. Glasziou, P. Harris, D. Hunt, A. Keech, S. MacMahon, P. Magnus, D. Newel, P. Nestel, N. Sharpe, J. Shaw, R. Simes, P. Thompson, A. Thompson, M. West, H. White, S. Simes, W. Hague, S. Caleo, Jane Hall, Andrew Martin, S. Mulray, P. Barter, L. Beilin, R. Collins, J. McNeil, P. Meier, H. Willimott, D. Smithers, P. Wallace, J. Baker, M. Hobbs, D. Sullivan, N. Anderson, G. Hankey, J. Watson, M. Arulchelvam, S. Chup, J. Daly, J. Hanna, A. Leach, M. Lee, J. Loughhead, H. Lundie-Jenkin, J. Morrison, S. Netting, A. Nguyen, H. Pater, R. Philip, G. Pinna, D. Rattos, S. Ryerson, V. Sazhin, R. Walsh, A. Claque, M. Mackie, J. Yallop, K. Boss, M. Shepard, J. Leach, M. Gandy, J. Joughin, J. Seabrook, R. Abraham, J. Allen, F. Bates, I. Beinart, E. Breed, D. Brown, N. Bunyan, D. Calvert, T. Campbell, D. Condon‐Paoloni, B. Conway, L. Coupland, J. Crowe, N. Cunio, B. Cuthbert, N. Cuthbert, S. D'arcy, P. Davidson, B. Dwyer, J. England, C. Friend, G. Fulcher, S. Grant, K. Hellestrand, M. Kava, L. Kritharides, D. McGill, H. McKee, A. Mclean, M. Neaverson, G. Nelson, M. O'Neill, C. Onuma, F. O'Reilly (1998)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.The New England journal of medicine, 339 19
G. Dunn (2004)
Statistical Evaluation of Measurement Errors: Design and Analysis of Reliability Studies
D. Sackett, R. Cook (1994)
Understanding clinical trialsBMJ, 309
D. Hilleman, Susan Heineman, P. Foral (2000)
Pharmacoeconomic Assessment of HMG‐CoA Reductase Inhibitor Therapy: An Analysis Based on the CURVES StudyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 20
I. Marschner, J. Emberson, L. Irwig, S. Walter (2004)
The number needed to treat (NNT) can be adjusted for bias when the outcome is measured with error.Journal of clinical epidemiology, 57 12
S. Walter, L. Irwig (2001)
Estimating the number needed to treat (NNT) index when the data are subject to errorStatistics in Medicine, 20
Drug development in the pharmaceutical industry is increasingly influenced by measures of cost‐effectiveness, such as cost per life‐year gained, and some governments make decisions about whether to pay for drugs based on cost‐effectiveness considerations. While cost per life‐year gained is a key measure of cost‐effectiveness, costs associated with the intermediate outcome of improving a biomarker, such as cholesterol level or blood pressure, provide important supplementary information, particularly where mortality data may be limited. In this case, cost‐effectiveness can be interpreted as the additional cost per unit time of achieving an additional beneficial biomarker response to treatment. A problem in this context is that biomarker assessment is typically subject to measurement error which leads to bias in assessing the benefit of a drug, and hence in the assessment of its cost‐effectiveness. We discuss the adjustment of cost‐effectiveness analyses for measurement error and consider the potential magnitude of bias that can arise. Using example calculations in the context of cholesterol‐lowering therapy, it is demonstrated that such biases can be significant, leading to costs being overestimated by in excess of 25%. Ignoring measurement error in cost‐effectiveness analyses can, therefore, have a substantial effect on the interpretation of such analyses. Copyright © 2006 John Wiley & Sons, Ltd.
Applied Stochastic Models in Business and Industry – Wiley
Published: Sep 1, 2006
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.